HUTCHMED China Limited (HCM) Actualités

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee 

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

— New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in...

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic...

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary...

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]